Investigational drug · Phase 3
BRC-201
Also called: TG-1000, Pixavir Marboxil
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BRC-201"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BRC-201", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BRC-201" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated InfluenzaPivotal-lookingRecruiting
Boryung Biopharma Co., Ltd.Industry
NCT07943390 · 348 participants (planned) · Start Nov 2026 · Primary completion Apr 2027
Drug: BRC-201; Placebo · For: Influenza
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Single-Dose Anti-Influenza Therapies: Current Progress and Future Perspectives.
Chen B, Li M, Zhang N, et al. · Clin Drug Investig 2026
- Mass balance, excretion, and pharmacokinetics of a single oral dose of [14C]pixavir marboxil in healthy Chinese male participants.
Zhao C, Yang Y, Liu G, et al. · Front Pharmacol 2026
- [Efficacy and safety of pixavir marboxil for uncomplicated influenza in adults: a phase ࡱ, randomized, double-blind, placebo-controlled clinical trial].
Chen MF, Sun YL, Yang Y, et al. · Zhonghua Jie He He Hu Xi Za Zhi 2026
- Pixavir Marboxil: First Approval.
Kang C · Drugs 2026
- Population Pharmacokinetics and Exposure-Response Analysis of Oral Pixavir Marboxil in Adults and Adolescents with Influenza.
Yang Y, Wang C, Liu X, et al. · Pharmaceutics 2026
- Altered Ocular Surface Temperature in Congenital Aniridia with PAX6 Pathogenic Variants: Impact of Age, Salzmann Nodules and Ocular Surgery.
Németh O, Náray A, Csidey M, et al. · Life (Basel) 2026
Also in development for Influenza
- Investigational Influenza VaccinePhase 34 trials
BioNTech SE · Influenza, COVID-19, COVID-19 (Coronavirus Disease 2019)
- GP681Phase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- GP681 SimulantPhase 32 trials
Jiangxi Qingfeng Pharmaceutical Co. Ltd. · Influenza, Human, Influenza
- mRNA-1018-H5Phase 31 trial
Moderna · Influenza
- Fluzone QudrivalentPhase 22 trials
Sanofi · Healthy Volunteers, Influenza Immunization, Influenza
- TRX-100Phase 22 trials
Traws Pharma, Inc. · Influenza
- ApomivirFE-L-APO, drug substancePhase 21 trial
Far East Bio-Tec Co., Ltd · Influenza
- OVX836Phase 21 trial
Osivax · Influenza
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.